Lotte Biologics CEO Richard Won-jik Lee announced the company’s full-fledged entry into the biopharma market as a CDMO at the 2023 JPMorgan Healthcare Conference.  (Source:Lotte Biologics)
Future Vision

Lotte Biologics Intends to Become a Global CDMO

Lotte Biologics has acquired the Syracuse plant in the United States from Bristol Myers Squibb Co. and now plans to expand it by adding ADC contract manufacturing services as well as clinical drug substance incubation and drug product facilities. The firm also plans to invest 3 billion dollars to develop three mega plants in Korea by 2030 with a total production capacity of 360,000 liters of antibody drugs.

Read on